Connect your AI

BioLife Solutions BLFS Intangibles (Net)

Intangibles (Net) at other companies

DanaherDHR

$17.17B-9.1%

AzentaAZTA

$91.43M—

LeMaitre VascularLMAT

$31.67M-7.9%

TEC

Bio-TechneTECH

$319.07M-28.1%

CryoPort, Inc.CYRX

$138.72M-4.6%

RevvityRVTY

$2.31B-10.3%

Other financials

Income statement

Revenue$27.5M+24.7%

Gross profit$17.5M+18.2%

Operating income$27.0K+105%

Net income$1.2M+365%

EPS (diluted)$0.02—

Balance sheet

Cash & equivalents$22.8M-65.9%

Total debt$17.4M-35.6%

Total equity$372.2M+5.6%

Total assets$400.9M+1.5%

Cash flow

Operating cash flow-$491.0K-128%

CapEx$167.0K-4.6%

Free cash flow-$658.0K-142%

Valuation

Market cap$1.25B+33.1%

Enterprise value$1.24B+38.1%

P/S12.5×+0.5×

Profitability

Gross margin66.9%—

Operating margin-16.7%—

Net margin-68.7%—

FCF margin-15.9%+18.7pp

Returns & leverage

Return on equity-14.5%-4.7pp

Debt / equity0×0.0×

Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BioLife Solutions's intangibles (net)?: BioLife Solutions (BLFS) reported intangibles (net) of $3.93M in Q1 2026.
How has BioLife Solutions's intangibles (net) changed year-over-year?: BioLife Solutions's intangibles (net) decreased by 55.6% year-over-year, from $8.86M to $3.93M.
What is the long-term trend for BioLife Solutions's intangibles (net)?: Over 5 years (2020 to 2025), BioLife Solutions's intangibles (net) has grown at a -32.8% compound annual growth rate (CAGR), from $31.05M to $4.26M.
What does intangibles (net) mean?: Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.